

First Class Mail

JC03 Rec'd PCT/PTO 31 MAR 2005 PCT

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

OIP TRANSMITTAL  
FORM

MAR 31 2005

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

6

Application Number

10/510,585

Filing Date

8 October 2004

First Named Inventor

Debra FLEENOR et al.

Art Unit

Examiner Name

Attorney Docket Number

2354 US F

## ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	corresponding EP 03718502.2
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	European Search Report [3 pp] and Return Card.
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Alcon Research, Ltd.		
Signature	<i>Teresa J. Schultz</i>		
Printed name	Teresa J. Schultz		
Date	28 March 2005	Reg. No.	40,526

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	<i>Barbara McKenzie</i>		
Typed or printed name	Barbara McKenzie	Date	28 March 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADE MARK OFFICE

In re Application of: Debra J. FLENNOR et al.

Serial No: 10/510,585

Filed: 8 October 2004

Examiner:

Group Art Unit:

FOR: Agents Which Regulate, Inhibit, Or Modulate The Activity And/Or Expression Of  
Connective Tissue Growth Factor (CTGF) As A Unique Means To Both Lower  
Intraocular Pressure And Treat Glaucomatous Retinopathies/Optic Neuropathies

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. 1.56, 1.97, AND 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit a copy of the corresponding European Search Report issued in the EP application is included for the Examiner's convenience. The references are listed on the attached PTO Form 1449.

Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

29 March 2005

Date

By:

Teresa J. Schultz

Teresa J. Schultz  
Registration No. 40,256  
817-551-4231

Address for Correspondence:  
Alcon Research, Ltd.  
Attn: Teresa J. Schultz  
6201 S. Freeway, Mail Code Q-148  
Fort Worth, TX 76134-2099  
Attorney Docket No.: 2354 US F

